Antisense oligonucleotides containing conformational constrained 2′,4′-(N-Methoxy)aminomethylene and 2′4′- aminooxymethylene and 2′-O,′-C-aminomethylene bridged nucleoside analogues show improved potency in animal models

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1636-1650

  Prakash, Thazha P ^a   Siwkowski, Andrew ^a   Allerson, Charles R ^a   Migawa, Michael T ^a   Lee, Sam ^a   Gaus, Hans J ^a   Black, Chris ^a   Seth, Punit P ^a   Swayze, Eric E ^a   Bhat, Balkrishen ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b REGULUS THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DI O ACETYL 3,5 O BI (2 (METHYL) NAPHTHALENE) 4 C (METHYLENEAMINOOXYMETHYL) ALPHA DEXTRO RIBOFURANOSE; 2' N,4' C [(N METHOXY)AMINOMETHYLENE]URIDINE; 2' O,4' C AMINOMETHYLENE NUCLEOSIDE; 2',4' (N METHOXY)AMINOMETHYLENE NUCLEOSIDE; 2',4' AMINOOXYMETHYLENE NUCLEOSIDE; 3' O (2 (METHYL) NAPHTHALENE) 5' O (TERT BUTYLDIPHENYLSILYL) 2' N, 4' C [(N METHOXY)AMINOMETHYLENE]URIDINE; 3,5 O BIS (2 (METHYL) NAPHTHALENE) 1,2 ISOPROPYLIDENE 4 C (METHYLENEAMINOOXYMETHYL) ALPHA DEXTRO RIBOFURANOSE; 3,5 O BIS (2 (METHYL) NAPHTHALENE) 1,2 ISOPROPYLIDENE 4 C (TRIFLUOROMETHANESULFONYLOXYMETHYL) ALPHA DEXTRO RIBOFURANOSE; 3,5 O BIS (2 (METHYL) NAPHTHALENE) 1,2 ISOPROPYLIDENE 4 C HYDROXYMETHYL ALPHA DEXTRO RIBOFURANOSE; 4 C (O METHANESULFONYL)HYDROXYMETHYL 3 O (2 (METHYL) NAPHTHALENE) 5 O (TERT BUTYL DIPHENYLSILYL) BETA DEXTRO ARABINOFURANOSYLURACIL; 4 C (O METHANESULFONYL)HYDROXYMETHYL 3 O (2 (METHYL) NAPHTHALENE) 5 O (TERT BUTYLDIPHENYLSILYL) 2 O TRIFLUOROMETHANESULFONYL) BETA DEXTRO ARABINOFURANOSYLURACIL; 4 C (O METHANESULFONYL)HYDROXYMETHYL 3 O 2 (METHYL) NAPHTHALENE 5 O (TERT-BUTYL TERT-BUTYLDIPHENYLSILYL) 2 O TRIFLUOROMETHANESULFONYL)BETA DEXTRO ARABINOFURANOSYLURACIL; 5' O (4,4' DIMETHOXYTRITYL) 2' N, 4' C (N METHYL)AMINOOXYMETHYLENEURINIDINE 3' [(2 CYANOETHYL) N,N DIISOPROPYL]PHOSPHORAMIDITE; 5' O (4,4' DIMETHOXYTRITYL) 2' N,4' C [(N METHOXY)AMINOMETHYLENE]URIDINE 3' [(2 CYANOETHYL) N, DIISOPROPYL]PHOSPHORAMIDITE; 5' O (TERT BUTYLDIPHENYLSILYL) 2' N,4' C [(N METHOXY)AMINOMETHYLENE]URIDINE; 5' O TERT BUTYLDIPHENYLSILYL 3' O (TERT-BUTYLDIMETHYLSILYL) 2' N,4' C [(N METHOXY)AMINOMETHYLENE]CYTIDINE; 5' O TERT BUTYLDIPHENYLSILYL 3' O (TERT-BUTYLDIMETHYLSILYL) 2' N,4' C [(N METHOXY)AMINOMETHYLENE]URIDINE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; IMIDAZOLE; N 4 BENZOYL 5 O (4,4' DIMETHOXYTRITYL) 2' N,4' C (N METHYL)AMINOOXYMETHYLENE)CYTIDINE 3' [(2 CYANOETHYL) N,N, DIISOPROPYL]PHOSPHORAMIDITE; N 4 BENZOYL 5' O (4,4' DIMETHOXYTRITYL) 2' N,4' C [(N METHOXY)AMINOMETHYLENE)CYTIDINE; N 4 BENZOYL 5' O (4,4' DIMETHOXYTRITYL) 2' N,4' C [(N METHOXY)AMINOMETHYLENE)CYTIDINE 3' [(2 CYANOETHYL) N,N DIISOPROPYL]PHOSPHORAMIDITE; NUCLEOSIDE ANALOG; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL;

ARTICLE; BODY WEIGHT; CHEMICAL BOND; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; KIDNEY; LIVER; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BODY WEIGHT; CELL LINE; DRUG STABILITY; HOT TEMPERATURE; MALE; MICE; MICE, INBRED BALB C; MOLECULAR CONFORMATION; NUCLEIC ACID DENATURATION; NUCLEIC ACID HETERODUPLEXES; OLIGORIBONUCLEOTIDES, ANTISENSE; ORGAN SIZE; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77649230488     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9013295     Document Type: Article

References (56)

1. Crooke, S. T., Ed. Antisense Drug Technology: Principles, Strategies, and Applications, 2nd ed.; CRC Press: Boca Raton, FL, 2007; 799 pp.
2. Group, V. S. Randomized dose-comparison studies of intravenous fomiversen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am. J. Ophthalmol.- 2002, 133, 475-483.
3. Eckstein, F. Phosphorothioate oligodeoxynucleotides: what is their origin, and what is unique about them? Antisense Nucleic Acid Drug Dev. 2000, 10, 117-121. (Pubitemid 30255596)
4. Geary, R. S.; Yu, R. Z.; Levin, A. A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Pain. Invest, Drugs 2001, 2, 562-573.
5. Manoharan, M. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration, and conjugation. Biochim. Biophys. Acta 1999,1489, 117-130.
6. Freier, S. M.; Altmann, K. H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemicallymodified DNA:RNA duplexes. Nucleic-1997,25,4429-4443.
7. Swayze, E. E.; Bhat, B. The Medicinal Chemistry of Oligonucleotides. In Antisense Drug Technology: Principles, Strategies, and Applications, 2nd ed.; Crooke, S. T., Ed.; CRC Press: Boca Raton, FL, 2008; pp 143-182.
8. Kurreck, J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003, 270, 1628-1644. (Pubitemid 36532522)
9. Lima, W. F.; Nichols, J. G.; Wu, H.; Prakash, T. P.; Migawa, M. T.; Wyrzykiewicz, T. K.; Bhat, B.; Crooke, S. T. Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J. Biol. Chem. 2004, 279, 36317-36326.
10. Monia, B. P.; Lesnik, E. A.; Gonzalez, C.; Lima, W. F.; McGee, D.; Guinosso, C. J.; Kawasaki, A. M.; Cook, P. D.; Freier, S. M. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 1993, 268, 14514-14522. (Pubitemid 23195583)
11. Martin, P. Ein neuer zugang zu 2-O-alkylribonucleosiden und eigenschaften deren, oligonucleotide. Hely. Chim, Atta 1995, 78, 486-504.
12. Teplova, M.; Minasov, G.; Tereshko, V.; Inamati, G. B.; Cook, P. D.; Manoharan, M.; Egli, M. Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 1999, 6, 535-539. (Pubitemid 29252831)
13. McKay, R.; Miraglia, L.; Cummins, L.; Owens, S.; Sasmor, H.; Dean, N. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human, protein kinase C-alpha expression. J. Biol, Chem. 1999, 274,1715-1722. (Pubitemid 129507766)
14. Altmann, K. H.; Martin, P.; Dean, N. M.; Monia, B. P. Second generation antisense oligonucleotides - inhibition of pkc-alpha and c-raf kinase expression by chimeric oligonucleotides incorporating 6′-substituted carbocyclic nucleosides and 2′-O-ethylene glycol substituted ribonucleosides. Nucleosides Nucleotides 1997, 16, 911-926.
15. Geary, R. S.; Watanabe, T. A.; Truong, L.; Freier, S.; Lesnik, E. A.; Sioufi, N. B.; Sasmor, H.; Manoharaon, M.; Levin, A. A. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 2001, 296, 890-897.
16. Yu, R. Z.; Geary, R. S.; Monteith, D. K.; Matson, J.; Truong, L.; Fitchett, J.; Levin, A. A. Tissue disposition of 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. 2004, 93, 48-59.
17. Geary, R. S.; Yu, R. Z.; Watanabe, T.; Henry, S. P.; Hardee, G. E.; Chappell, A.; Matson, J.; Sasmor, H.; Cummins, L.; Levin, A. A. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species, Drug Metab. 9S- 2003, 31, 1419-1428.
18. Zhang, H.; Cook, J.; Nickel, J.; Yu, R.; Stecker, K.; Myers, K.; Dean, N. M. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 2000,18, 862-867.
19. Yu, R. Z.; Zhang, H.; Geary, R. S.; Graham, M.; Masarjian, L.; Lemonidis, K.; Crooke, R.; Dean, N. M.; Levin, A. A. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol Exp. 2k£- 2001, 296, 388-395. (Pubitemid 32112464)
20. Liang, Y.; Osborne, M. C.; Monia, B. P.; Bhanot, S.; Watts, L. M.; She, P.; Decarlo, S. O.; Chen, X.; Demarest, K. Antisense oligonucleotides targeted, against glucocorticoid, receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metablism 2005, 54, 848-855. (Pubitemid 40827198)
21. Zinker, B. A.; Rondinone, C. M.; Trevillyan, J. M.; Gum, R. J.; Clampit, J. E.; Waring, J. F.; Xie, N.; Wilcox, D.; Jacobson, P.; Frost, L.; Kroeger, P. E.; Reilly, R. M.; Koterski, S.; Opgenorth, T. J.; Ulrich, R. G.; Crosby, S.; Butler, M.; Murray, S. F.; McKay, R. A.; Bhanot, S.; Monia, B. P.; Jirousek, M. R. PTPlB antisense oligonucleotide lowers PTPlB protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc, NgH, Acad. Sci U.S.A. 2002, 99, 11357-11362.
22. Butler, M.; McKay, R. A.; Popoff, I. J.; Gaarde, W. A.; Witchell, D.; Murray, S. F.; Dean, N. M.; Bhanot, S.; Monia, B. P. Specific inhibition, of PTEN expression, reverses hyperglycemia in diabetic mice. Diabetes 2002, 51, 1028-1034.
23. Crooke, R. M.; Graham, M. J.; Lemonidis, K. M.; Whipple, C. P.; Koo, S.; Perera, R. J. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid- 2005, 46, 872-884.
24. Kastelein, J. J.; Wedel, M. K.; Baker, B. F.; Su, J.; Bradley, J. D.; Yu, R. Z.; Chuang, E.; Graham, M. J.; Crooke, R. M. Potent reduction of apolipoprotein B and LDL cholesterol by short-term administration of an antisense inhibitor of apolipoprotein. B. Circulation 2006, 114, 1729-1735.
25. Chi, K. N.; Eisenhauer, E.; Fazli, L.; Jones, E. C.; Goldenberg, S. L.; Powers, J.; Tu, D.; Gleave, M. E. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 2005, 97,1287-1296.
26. Sewell, K. L.; Geary. R. S.: Baker, B. F.; Glover, J. M.: Mant, T. G.; Yu, R. Z.; Tami, J. A.; Dorr, F. A. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther- 2002, 303, 1334-1343.
27. Obika, S.; Nanbu, D.; Hari, Y.; Andoh, J.; Morio, K.; Doi, T.; Imanishi, T. Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron. 1997, 38, 8735-8738. (Pubitemid 27504436)
28. Obika, S.; Nanbu, D.; Hari, Y.; Andoh, J.; Morio, K.; Doi, T.; Imanishi, T. Stability and structural features of the duplexes containing nucleoside analogs with a fixed. N-type conformation, 2′-O,4′-C- methyleneribonucleosides. Tetrahedron Lett- 1998, 39, 5401-5404.
29. Wengel, J. Synthesis of 3′-C- and 4′-C-branched oligodeoxynucleotides and the development of locked nucleic acid. (LNA). Acc. Chem. Res. 1999, 32, 301-310.
30. Koshkin, A. A.; Nielsen, P.; Meldgaard, M.; Rajwanshi, V. K.; Singh, S. K.; Wengel, J. LNA (locked nucleic acid): an RNA mimic forming exceedingly stable LNA:LNA duplexes. J. Am. Chem. Soc. 1998, 120, 13252-13253.
31. Fluiter, K.; Frieden, M.; Vreijling, J.; Rosenbohm, C.; De Wissel, M. B.; Christensen, S. M.; Koch, T.; Oram, H.; Baas, F. On the in vitro and in vivo properties of four locked, nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. ChemBioChem 2005, 6, 1104-1109. (Pubitemid 40825353)
32. Swayze, E. E.; Siwkowski, A. M.; Wancewicz, E. W.; Migawa, M. T.; Wyrzykiewicz, T. K.; Hung, G.; Monia, B. P.; Bennett, C. F. Antisense oligonucleotides containing locked, nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 2007, 35, 687-700.
33. Seth, P. P.; Siwkowski, A.; Allerson, C. R.; Vasquez, G.; Lee, S.; Prakash, T. P.; Kinberger, G.; Migawa, M. T.; Gaus, H.; Bhat, B.; Swayze, E. E. Design, synthesis and evaluation, of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. Nucleic Acids Symp. Ser. 2008, 553-554.
34. Seth, P. P.; Siwkowski, A.; Allerson, C. R.; Vasquez, G.; Lee, S.; Prakash, T. P.; Wancewicz, E. V.; Witchell, D.; Swayze, E. E. Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased, toxicity in animals. J. Md, Chem. 2009, 52,10-13.
35. AbdurRahman, S. M.; Seki, S.; Obika, S.; Yoshikawa, H.; Miyashita, K.; Imanishi, T. Design, synthesis, and properties of 2′,4′-BNANC: a bridged, nucleic acid analogue. J. Am, Chem. Soc. 2008,130,4886-4896.
36. Prakash, T. P.; Johnston, J. F.; Graham, M. J.; Condon, T. P.; Manoharan, M. 2′-O-[2-[(N,N-Dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. Nuclei Acids Res. - 2004, 32, 828-833. (Pubitemid 38263076)
37. Seth, P. P.; Swayze, E. E. 6-Modified Bicyclic Nucleic Acid Analogs. U.S. Patent 7399845, 2008; Isis Pharmaceuticals, Inc.
38. Divakar, K. J.; Reese, C. B. 4-(l,2,4-Triazol-l-yl)- and 4-(3-nitrol,2,4-triazol-l-yl)-l-(b-D-2,3,5-tri-O-acetylarabinofuranosyl) pyrimidin-2(1H)-ones. Valuable intermediates in the synthesis of derivatives of l-(b-D-arabinofuranosyl)cytosine (ara-C). J. Chem. Soc. Perkin Trans. 1 1982. 1171-1176.
39. Bhat, V.; Ugarkar, B. G.; Sayeed, V. A.; Grimm, K.; Kosora, N.; Domenico, P. A.; Stocker, E. A simple and convenient method for the selective N-acylations of cytosine nucleosides. Nucleosides Nucleotides 1989, 8, 179-183. (Pubitemid 19093572)
40. Prakash, T. P.; Kawasaki, A. M.; Fraser, A. S.; Vasquez, G.; Manoharan, M. Synthesis of 2′-O-[2-[(N,N-dimethylamino)oxy]ethyl] modified, nucleosides and oligonucleotides. J. Org. Chem. 2002, 67, 357-369. (Pubitemid 34101238)
41. Vorbrueggen, H.; Bennua, B. Nucleoside syntheses. XXV. A new simplified nucleoside synthesis. Chem. Ber. 1981, 114,1279-1286.
42. Butler, M.; McKay, R. A.; Popoff, I. J.; Gaarde, W. A.; Witchell, D.; Murray, S. F.; Dean, N. M.; Bhanot, S.; Monia, B. P. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 2002, 51, 1028-1034.
43. Butler, M. M., R.; Popof, I. J.; Gaarde, W. A.; Witchell, D; Murray, S. F.; Dean, N. M.; Bhanot, S; Monia, B. P. Specific inhibition, of PTEN expression, reverses hyperglycemia in diabetic mice. Diabetes 2002, 51, 1028-1034.
44. Cheruvallath, Z. S.: Carty. R. L.; Moore, M. N.: Capaldi, D. C: Krotz, A. H.; Wheeler, P. D.; Turney, B. J.; Craig, S. R.; Gaus, H. J.; Scozzari, A. N.; Cole, D. L.; Ravikumar, V. T. Synthesis of antisense oligonucleotides: replacement of 3H-l,2-benzodithiol3-one 1,1-dioxide (Beaucage reagent) with phenylacetyl disulfide (PADS) as efficient sulfurization reagent: from bench to bulk manufacture of active pharmaceutical ingredient. Orz. Process Res. Dev. 2000, 4, 199-204.
45. Guzaev, A. P.; Manoharan, M. A conformationally preorganized universal solid support for efficient oligonucleotide synthesis. J. Am, Chem. Soc. 2003, 125, 2380-2381. (Pubitemid 36512210)
46. Wang, Z.; Olsen, P.; Ravikumar, V. T. A novel universal linker for efficient synthesis of phosphorothioate oligonucleotides. Nucleosides, Nucleotides Nucleic Acids 2007, 26, 259-269.
47. Wang, Z.; Siwkowski, A.; Lima,W. F.; Olsen, P.; Ravikumar,V. T. Antisense oligonucleotides: efficient synthesis of 2′-O-methoxyethyl phosphorothioate oligonucleotides using 4,5-dicyanoimidazole. Are these oligonucleotides comparable to those synthesized using 1 H-tetrazole as coupling activator? Bioorg. Med. Chem. 2006, 14, 5049-5060.
48. Zhou, C.; Liu, Y.; Andaloussi, M.; Badgujar, N.; Plashkevych, O.; Chattopadhyaya, J. Fine tuning of electrostatics around trie internucleotidic phosphate through incorporation of modified 2′,4′carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties. J. Org. Chem. 2009, 74,118-134.
49. Saenger, W. Principles of Nucleic Acid Structure; Springer-Verlag: New York, 1984.
50. Freier, S. M.; Altmann, K.-H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemicallymodified DNA:RNA duplexes. Nucleic Acids Res. 1997, 25, 4429-4443.
51. Koizumi, M.; Takagi-Sato, M.; Okuyama, R.; Araki, K.; Sun, W.; Nakai, D.; Tsutsumi, S.; Kawai, K. Direct comparison, of in vivo antisense activity of ENA oligonucleotides targeting PTPlB mRNA with that of 2′-O-(2-methoxy)ethyl- modified oligonucleotides. Oligonucletides 2006, 16, 253-262. (Pubitemid 44763319)
52. Alul, R. H.; Singman, C. N.; Zhang, G. R.; Letsinger, R. L. OxalylCPG: a labile support for synthesis of sensitive oligonucleotide derivatives. Nucleic Acids Res. 1991, 19, 1527-1532.
53. Geary, R. S.; Wancewicz, E.; Matson, J.; Pearce, M.; Siwkowski, A.; Swayze, E.; Bennett, F. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem. Pharmacol. 2009, 78, 284-291.
54. Committee on Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals; DHHS Publication No. 85-23, 26; National Institutes of Health: Bethesda, MD, 1985.
55. Yu, R. Z.; Kim, T. W.; Hong, A.; Watanabe, T. A.; Gaus, H. J.; Geary, R. S. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. J. Pharmacol. Exp.Ther. 2007, 35, 460-468.
56. Lesnik, E. A.; Freier, S. M. What affects the effect of 2′-alkoxy modifications? 1. Stabilization effect of 2′-methoxy substitutions in uniformly modified DNA oligonucleotides. Biochemistry 1998, 37, 6991-6997.